Full Press Release Details
Reports 94% Increase in CGuard EPS Revenues
for the Second Quarter of 2018
Aviv, Israel- August 6, 2018 - InspireMD, Inc. (NYSE American:NSPR), developer of the CGuard Embolic Prevention System
(EPS) for the prevention of stroke caused by the treatment of carotid artery disease, today announced results for the second quarter
ending June 30, 2018.
Quarter 2018 highlights:
| Revenues in Q2 of $1.0 million for 2018 versus $640,000 in 2017, an increase of 57% | |
| CGuard EPS revenues in Q2 of $833,000 for 2018 versus $430,000 in 2017, an increase of 94% | |
| $6.4 million of cash at June 30, 2018, not including $6.4 million in net proceeds from capital raised in Q2 but received in early July 2018 | |
| All the Redeemable Preferred Shares were redeemed in early July with proceeds from the most recent stock offering |
Barry, PhD, Chief Executive Officer of InspireMD, commented, "We are pleased to report another strong quarter with 94% year-over-year
growth in sales of CGuard EPS, with total sales in excess of $1 million for the second quarter of 2018. We achieved these
results while in the midst of transitioning our sales and marketing strategy from KOLs, where we are already generating strong
adoption, to mainstream physicians, as previously discussed. In particular, we are more aggressively targeting vascular surgeons,
who currently treat the majority of patients with carotid artery disease with open surgery. Vascular surgeons have been slow to
adopt carotid arterial stenting (CAS) due to stroke risks associated with conventional stents. The response from these vascular
surgeons has been positive and when presented with a safe, minimally invasive option, they have shown a willingness to adopt the
CGuardTM EPS over the more invasive surgical procedure (CEA) for their patients. We believe expanding into the vascular
surgery market segment would significantly expand the addressable market for our product. Importantly, there are 2.2 million people
diagnosed with high grade carotid stenosis each year, but only six hundred thousand, or 30%, receive a surgical or stent procedure.
This is due, in large part, to the risks associated with traditional procedures. As a result, we see an untapped market of at
least 1.6 million additional patients per year that could be helped with CGuard EPS as a safer alternative to traditional
procedures. With our recent capital raise completed, we are accelerating our commercial activities. We expect to see the impact
of this investment, along with our expanded sales and marketing initiatives as we end this year and head into the new year."
the market has been extremely receptive to CGuardTM EPS. In addition to rapid revenue growth, we have had featured
presentations at top industry conferences in just the past quarter including the SBHCI Congress in Brazil, the 10th International
Congress of the Polish Society for Vascular Surgery, a live case transmission to the 2nd DGA Interventional Congress, and EuroPCR
2018 where we presented the expanded 24 month follow-up results from the PARADIGM-Extend Clinical Study utilizing CGuard
EPS. Cumulative data in the PARADIGM-Extend Clinical Study showed no major strokes in the peri-procedural or post-procedural period
up to 30 days (0%) and there were no stroke or stroke-related deaths between 12 and 24 months. In addition, the duplex ultrasound
data confirmed normal vessel healing with CGuard EPS with no indication of any long term in-stent restenosis. These results
included a significant proportion of challenging patients that would have otherwise been sent to surgery (carotid endarterectomy).
Importantly, these and other clinical data suggest that CGuard EPS may offer a safer alternative to the surgical gold standard
of carotid endarterectomy (CEA)."
as previously disclosed, we have met with the FDA regarding our investigational device exemption (IDE) submission for CGuard
EPS, and, having completed our recent financing, we are actively working on this submission. We look forward to providing further
updates in the coming months."
for the second quarter ended June 30, 2018 was $1,003,000 compared to $640,000 during the same period in 2017. The increase was
primarily due to an increase in sales of CGuard EPS as a result of our continued focus on expanding existing markets such
as Germany, Italy and Russia, our transition from our prior exclusive distribution partner for most of Europe to local distributors
and expanding into new geographies such as India. The Company's gross profit for the quarter ended June 30, 2018 was $277,000
compared to $147,000 for the same period in 2017. Gross margin increased to 27.6% in the three months ended June 30, 2018 from
23.0% in the same period in 2017, driven mainly by higher volume and more efficient utilization of our fixed manufacturing resources.
operating expenses for the quarter ended June 30, 2018 were $1,750,000, a decrease of 28.3% compared to $2,441,000 for the same
period in 2017. This decrease was primarily due to a decrease in salary expenses, primarily due to a salary related accrual in
2017 and a decrease in share-based compensation expenses. Financial income for the quarter ended June 30, 2018 was $846,000 compared
to $0 for the same period in 2017, largely due to non-cash income associated with our preferred stock. Net loss for the quarter
ended June 30, 2018 totaled $627,000, or $0.15 per basic and diluted share, compared to a net loss of $2,294,000, or $7.30 per
basic and diluted share, in the same period in 2017.
for the six months ended June 30, 2018 was $2,010,000 compared to $1,209,000 during the same period in 2017. The increase was
primarily due to an increase in sales of CGuard EPS as a result of our transition from our prior exclusive distribution
partner for most of Europe to local distributors, continued focus on expanding existing markets such as Germany and Italy and
expanding into new geographies such as India. The Company's gross profit for the six months ended June 30, 2018 was $570,000
compared to $221,000 for the same period in 2017. Gross margin increased to 28.4% in the six months ended June 30, 2018 from 18.3%
in the same period in 2017, driven mainly by higher volume and more efficient utilization of our fixed manufacturing resources.
operating expenses for the six months ended June 30, 2018 were $3,996,000, a decrease of 18.8% compared to $4,919,000 for the
same period in 2017. This decrease was primarily due to a decrease in salary expenses, primarily due to a salary related accrual
in 2017 and a decrease in share-based compensation expenses, partially offset by an increase in legal expenses. Financial income
for the six months ended June 30, 2018 was $410,000 compared to $154,000 of financial expenses for the same period in 2017, largely
due to non-cash income associated with our preferred stock. Net loss for the six months ended June 30, 2018 totaled $3,016,000,
or $0.76 per basic and diluted share, compared to a net loss of $4,853,000, or $25.64 per basic and diluted share, in the same
of June 30, 2018, cash and cash equivalents were $6,442,000, compared to $3,710,000 as of December 31, 2017. The June 30, 2018
cash balance does not include $6.4 million in net proceeds from capital raised in Q2 2018
but received in early July 2018.
seeks to utilize its proprietary MicroNet technology to make its products the industry standard for Carotid Stenting by providing
outstanding acute results and durable stroke free long term outcomes.
common stock is quoted on the NYSE American under the ticker symbol NSPR and certain warrants are quoted on the NYSE American
under the ticker symbol NSPR.WS.
press release contains "forward-looking statements." Such statements may be preceded by the words "intends,"
"may," "will," "plans," "expects," "anticipates," "projects,"
"predicts," "estimates," "aims," "believes," "hopes," "potential"
or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are
subject to various known and unknown risks and uncertainties, many of which are beyond the Company's control, and cannot
be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking
statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) market acceptance
of our existing and new products, (ii) negative clinical trial results or lengthy product delays in key markets, (iii) an inability
to secure regulatory approvals for the sale of our products, (iv) intense competition in the medical device industry from much
larger, multinational companies, (v) product liability claims, (vi) product malfunctions, (vii) our limited manufacturing capabilities
and reliance on subcontractors for assistance, (viii) insufficient or inadequate reimbursement by governmental and other third
party payers for our products, (ix) our efforts to successfully obtain and maintain intellectual property protection covering
our products, which may not be successful, (x) legislative or regulatory reform of the healthcare system in both the U.S. and
foreign jurisdictions, (xi) our reliance on single suppliers for certain product components, (xii) the fact that we will need
to raise additional capital to meet our business requirements in the future and that such capital raising may be costly, dilutive
or difficult to obtain and (xiii) the fact that we conduct business in multiple foreign jurisdictions, exposing us to foreign
currency exchange rate fluctuations, logistical and communications challenges, burdens and costs of compliance with foreign laws
and political and economic instability in each jurisdiction. More detailed information about the Company and the risk factors
that may affect the realization of forward looking statements is set forth in the Company's filings with the Securities
and Exchange Commission (SEC), including the Company's Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q.
Investors and security holders are urged to read these documents free of charge on the SEC's web site at http://www.sec.gov.
The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information,
future events or otherwise.
STATEMENTS OF OPERATIONS (1)
dollars in thousands, except per share data)
| Three months ended | Six months ended | |||||||||||||||
| June 30, | June 30, | |||||||||||||||
| 2018 | 2017 | 2018 | 2017 | |||||||||||||
| Revenues | $ | 1,003 | $ | 640 | $ | 2,010 | $ | 1,209 | ||||||||
| Cost of revenues | 726 | 493 | 1,440 | 988 | ||||||||||||
| Gross Profit | 277 | 147 | 570 | 221 | ||||||||||||
| Operating Expenses: | ||||||||||||||||
| Research and development | 230 | 403 | 482 | 753 | ||||||||||||
| Selling and marketing | 580 | 632 | 1,072 | 1,164 | ||||||||||||
| General and administrative | 940 | 1,406 | 2,442 | 3,002 | ||||||||||||
| Total operating expenses | 1,750 | 2,441 | 3,996 | 4,919 | ||||||||||||
| Loss from operations | (1,473 | ) | (2,294 | ) | (3,426 | ) | (4,698 | ) | ||||||||
| Financial expenses (income) | (846 | ) | - | (410 | ) | 154 | ||||||||||
| Loss before tax expenses | (627 | ) | (2,294 | ) | (3,016 | ) | (4,852 | ) | ||||||||
| Tax expenses (Income) | - | - | - | 1 | ||||||||||||
| Net Loss | $ | (627 | ) | $ | (2,294 | ) | $ | (3,016 | ) | $ | (4,853 | ) | ||||
| Net loss per share - basic and diluted | $ | (0.15 | ) | $ | (7.30 | ) | $ | (0.76 | ) | $ | (25.64 | ) | ||||
| Weighted average number of shares of common stock used in computing net loss per share - basic and diluted | 6,745,360 | 313,812 | 4,511,681 | 213,840 |
dollars in thousands)
| June 30, 2018 | December 31, 2017 | |||||||
| ASSETS | ||||||||
| Current Assets: | ||||||||
| Cash and cash equivalents | $ | 6,442 | $ | 3,710 | ||||
| Accounts receivable: | ||||||||
| Trade, net | 916 | 643 | ||||||
| Other | 175 | 207 | ||||||
| Prepaid expenses | 71 | 62 | ||||||
| Inventory | 637 | 533 | ||||||
| Total current assets | 8,241 | 5,155 | ||||||
| Non-current assets: | ||||||||
| Property, plant and equipment, net | 431 | 476 | ||||||
| Deferred Issuance Costs | 310 | - | ||||||
| Funds in respect of employee rights upon retirement | 489 | 476 | ||||||
| Total non-current assets | 1,230 | 952 | ||||||
| Total assets | $ | 9,471 | $ | 6,107 |
| June 30, 2018 | December 31, 2017 | |||||||
| LIABILITIES AND EQUITY | ||||||||
| Current liabilities: | ||||||||
| Accounts payable and accruals: | ||||||||
| Trade | $ | 476 | $ | 328 | ||||
| Other | 1,978 | 2,134 | ||||||
| Contract liability | 26 | 20 | ||||||
| Total current liabilities | 2,480 | 2,482 | ||||||
| Long-term liabilities: | ||||||||
| Liability for employees rights upon retirement | 629 | 624 | ||||||
| Total long-term liabilities | 629 | 624 | ||||||
| Total liabilities | 3,109 | 3,106 | ||||||
| Redeemable preferred shares | 2,264 | 274 | ||||||
| Equity: | ||||||||
| Common stock, par value $0.0001 per share; 150,000,000 shares authorized at June 30, 2018 and December 31, 2017; 6,453,428 and 1,483,556 shares issued and outstanding at June 30, 2018 and December 31, 2017, respectively | - | - | ||||||
| Preferred B shares, par value $0.0001 per share; 500,000 shares authorized at June 30, 2018 and December 31, 2017; 17,303 and 27,075 shares issued and outstanding at June 30, 2018 and December 31, 2017, respectively | - | - | ||||||
| Preferred C shares, par value $0.0001 per share; 1,172,000 shares authorized at June 30, 2018 and December 31, 2017; 378,840 (3) and 741,651 shares issued and outstanding at June 30, 2018 and December 31, 2017, respectively | - | - | ||||||
| Preferred D shares, par value $0.0001 per share; 750 shares authorized at June 30, 2018 and December 31, 2017; 300 (4) and 750 shares issued and outstanding at June 30, 2018 and December 31, 2017, respectively | - | - | ||||||
| Additional paid-in capital | 147,466 | 143,079 | ||||||
| Accumulated deficit | (143,368 | ) | (140,352 | ) | ||||
| Total equity | 4,098 | 2,727 | ||||||
| Total liabilities, redeemable preferred shares and equity | $ | 9,471 | $ | 6,107 |
All 2018 financial information is derived from the Company's 2018 unaudited financial statements, as disclosed in the Company's
Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission; all 2017 financial information is derived from
the Company's 2017 unaudited financial statements, as disclosed in the Company's Quarterly Report on Form 10-Q, filed
with the Securities and Exchange Commission.